ACCURAY INC (ARAY) FY2025 10-K Annual Report
ACCURAY INC (ARAY) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Aug 28, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ACCURAY INC FY2025 10-K Analysis
Business Overview
- • Core business model: Development and sale of advanced radiation therapy systems including CyberKnife robotic radiosurgery and TomoTherapy helical radiation platforms
- • New product emphasis: Introduction of Accuray Helix CT-guided helical radiotherapy system combining affordability and automation to expand radiation access
- • Strategic shift: Expanded international sales focus with new direct offices and distributors plus key collaborations including 2024 AI radiotherapy system performance prediction with Airbus
- • Quantitative highlight: CyberKnife S7 System enables treatment plans up to 90% faster and treatments up to 50% faster, enhancing clinical efficiency
- • Noteworthy fact: 2025 filing highlights novel AI-driven real-time tumor tracking tech (Synchrony) integrated with motion-adaptive treatment delivery as a market differentiator
Management Discussion & Analysis
- • Revenue impact negative from U.S. reduced budgets and longer installations, continuing through FY2026, no specific revenue $ reported
- • Gross margin and net income adversely affected by inflation, supply chain, freight costs; impact expected through at least calendar year 2025, no margin % given
- • Approximately 70% raw materials U.S.-sourced; 80%+ products exported; tariff uncertainties may reduce sales to China through H1 FY2026
- • No fiscal 2025 bonuses paid to comply with debt covenants and conserve cash amid uncertain macroeconomic environment
- • Management monitoring liquidity, customer and supplier actions, evaluating operating expenses and real estate usage for cost control
Risk Factors
- • Regulatory risk from FDA and other clearances, critical for product sales and R&D costs impacting future capital needs
- • Macroeconomic exposure to China anti-corruption campaign and stimulus timing, affecting operations and liquidity forecasts
- • Supply chain cost inflation raised inventory costs by $9.1 million, pressuring gross margins through 2025
- • Convertible Notes refinancing risk with $18 million principal still due June 2026, backed by $20 million delayed draw facility
- • Competitive threat from evolving technologies impacting the demand forecast assumptions used in inventory valuation and reserves
ACCURAY INC FY2025 Key Financial MetricsXBRL
Revenue
$459M
▲ +2.7% YoY
Net Income
-$2M
▲ +89.8% YoY
Gross Margin
32.1%
▲ +5bp YoY
Operating Margin
1.7%
▲ +160bp YoY
Net Margin
-0.3%
▲ +313bp YoY
ROE
-2.0%
▲ +3252bp YoY
Total Assets
$470M
▲ +0.3% YoY
EPS (Diluted)
$-0.02
▲ +87.5% YoY
Operating Cash Flow
$3M
▲ +124.0% YoY
Source: XBRL data from ACCURAY INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ACCURAY INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.